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Transcatheter aortic valve implantationa b s t r a c t
Background: A new staging classification of aortic stenosis (AS) characterizing the extent of cardiac
damage was established and validated in patients undergoing transcatheter aortic valve implantation
(TAVI). The present study was aimed to refine the staging system by integrating a quantitative evaluation
of right ventricular (RV) dysfunction defined by current echocardiographic guideline recommendations.
Methods and results: In a prospective TAVI registry, patients were categorized into the stages: no cardiac
damage (Stage 0), left ventricular damage (Stage 1), left atrial or mitral valve damage (Stage 2),
pulmonary vasculature or tricuspid valve damage (Stage 3), or RV damage (Stage 4) based on baseline
echocardiography. Among 1133 eligible patients undergoing TAVI, 8 (3.4%) patients were categorized
as Stage 0, 113 (10.0%) as Stage 1, 397 (35.0%) as Stage 2, 239 (21.1%) as Stage 3, and 346 (30.5%) as
Stage 4. There was a stepwise increase in all-cause and cardiovascular mortality rates at 1 year according
to increasing stages of secondary cardiac damage: 5.4% and 0% in Stage 0, 5.3% and 1.8% in Stage 1, 8.9%
and 5.9% in Stage 2, 17.7% and 12.9% in Stage 3, and 25.8% and 19.9% in Stage 4, respectively. After
multivariable adjustment, increasing stages of cardiac damage gradually correlated with all-cause and
cardiovascular mortality.
Conclusion: A significant number of patients with AS underwent TAVI only once cardiac damage has
already occurred. Integrating a guideline-based definition of RV dysfunction increased the sensitivity
of the staging system to identify patients at increased risk of death after TAVI.
 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Safety and efficacy of aortic valve replacement for the treatment
of aortic stenosis (AS) is well established [1]. There is however a
lack of evidence surrounding the optimal timing of intervention
[2–5]. Premature valvular replacement may expose patients to
unnecessary peri-procedural risks while exchanging disease of
the native aortic valve against the process of prosthetic valve
degeneration and thrombosis. Conversely, delayed intervention
may lead to irreversible myocardial damage that may increase
peri-procedural risks and affect long-term clinical outcomes
despite valvular replacement therapy. Recently, a staging system
has been proposed to quantify the extent of cardiac damageassociated with AS [6]. The classification was originally derived
based on data from the PARTNER trial [6], and further validated
in an independent cohort of 689 patients who underwent tran-
scatheter aortic valve implantation (TAVI) at Pittsburg Medical
Center [7]. In both studies, right ventricular (RV) damage was qual-
itatively estimated by visual assessment. This resulted in substan-
tially lower rates of RV dysfunction (8.7% and 4%, respectively) as
compared to the reported prevalence of RV dysfunction in a recent
meta-analysis (37%) [8]. In another validation study conducted in
1189 symptomatic severe AS patients [9,10], RV dysfunction was
quantitatively assessed using tricuspid annular plane systolic
excursion (TAPSE) < 1.6 cm, based on an old echocardiographic
guideline [11]. In the study, RV dysfunction was identified in
12%, rather higher than the high-risk TAVI cohorts. Thus, we sought
to refine and validate the proposed staging system by integrating a
quantitative evaluation of RV dysfunction defined by latest
echocardiographic guidelines [12].
T. Okuno, D. Heg, J. Lanz et al. IJC Heart & Vasculature 33 (2021) 1007682. Materials and methods
AS patients undergoing TAVI were consecutively enrolled into a
prospective registry at Bern University Hospital, Bern, Switzerland
(NCT01368250) [13]. The registry was approved by the local ethics
committee, and patients providedwritten informed consent for par-
ticipation. Based on transthoracic/transesophageal echocardiogra-
phy performed within 3 months before TAVI, patients were
retrospectively categorized into the following stages: Stage 0: no
cardiac damage; Stage 1: left ventricular (LV) damage (LV ejection
fraction < 60%, LV mass index > 95 g/m2 for women, >115 g/m2 for
men, or LV diastolic dysfunction  grade II [14]); Stage 2: left atrial
(LA) or mitral valve damage (LA volume index > 34 ml/m2, mitral
regurgitation  moderate, or presence of atrial fibrillation); Stage
3: pulmonary vasculature or tricuspid valve damage (systolic pul-
monary artery pressure  60 mmHg, or tricuspid
regurgitation  moderate); Stage 4: RV damage (RV dysfunction)
(Fig. 1).
RV dysfunction was documented in the presence of at least
two of the following parameters: TAPSE < 1.7 cm, S’ <9.5 cm/s,
and fractional area change (FAC) < 35% [12]. If only two param-
eters were available and discrepant, RV dysfunction was defined
by prioritizing in the order of TAPSE, S’, and FAC. All echocardio-
graphic studies were re-evaluated by dedicated and experienced
imaging specialists. Patients were hierarchically categorized into
the most advanced stage if at least one of the criteria was met
within that stage. Patients who could not be classified in any
of the stages due to missing data were excluded from the pre-
sent analysis.Fig. 1. Prevalence of stages of cardiac damage and cardiovascular mortality. *LV hypert
accordance with the guideline recommendations [12,14]. LV = left ventricular; LA
PASP = pulmonary artery systolic pressure.
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Clinical follow-up was performed by standardized interviews,
documentation from referring physicians, and hospital discharge
summaries at 1 year. Mortality data were systematically collected
and adjudicated by a dedicated clinical events committee accord-
ing to the Valve Academic Research Consortium (VARC-2) recom-
mendations [15].
Categorical variables are presented as frequencies and percent-
ages, and the differences between groups were evaluated using the
chi-square test or Fisher’s exact test. Continuous variables are pre-
sented as mean values ± standard deviation (SD), and were com-
pared between groups using F test. Cumulative event curves of
all-cause and cardiovascular mortality were constructed using
the Kaplan-Meier method. Univariate and multivariate Cox propor-
tional hazards models were used to calculate hazard ratios (HR)
and 95% confidence intervals (95% CI). Multivariable adjustment
was performed with baseline variables selected based on pre-
sumed association with mortality as well as those that may cause
cardiac damage independently of AS: age, sex, body surface area,
New York Heart Association (NYHA) functional class III or IV, Soci-
ety of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM),
hypertension, chronic kidney disease, coronary artery disease,
moderate or severe mitral stenosis, chronic obstructive pulmonary
disease (COPD), previous cardiac surgery, previous pacemaker
implantation. A sensitivity analysis excluding patients with the
comorbidities that may affect cardiac staging independently of
AS were performed: coronary artery disease, moderate or severe
mitral stenosis, COPD, previous cardiac surgery, and previous pace-
maker implantation. All statistical analyses were performed using
Stata 15.1 (StataCorp, College Station, TX, USA).rophy, LV diastolic dysfunction, LA dilatation, and RV dysfunction were defined in
= left atrial; RV = right ventricular; LVEF = left ventricular ejection fraction;
Table 1
Baseline characteristics according to cardiac damage.
All patients
(n = 1,133)









Age (years) 82.1 ± 6.3 80.5 ± 6.6 82.7 ± 5.5 83.1 ± 5.7 81.4 ± 7.2 <0.001
Gender (female) 576 (50.8%) 82 (54.3%) 190 (47.9%) 155 (64.9%) 149 (43.1%) <0.001
Body surface area (m2) 1.82 ± 0.23 1.82 ± 0.24 1.85 ± 0.23 1.80 ± 0.23 1.81 ± 0.22 0.029
STS-PROM 6.07 ± 4.22 4.32 ± 2.70 5.37 ± 3.38 6.89 ± 5.05 7.08 ± 4.59 <0.001
NYHA III or IV 775 (68.5%) 88 (58.3%) 258 (65.2%) 167 (69.9%) 262 (75.9%) <0.001
Hypertension 946 (83.5%) 123 (81.5%) 338 (85.1%) 202 (84.5%) 283 (81.8%) 0.543
Chronic kidney disease (eGFR < 60) 809 (71.5%) 91 (60.3%) 270 (68.0%) 184 (77.0%) 264 (76.5%) <0.001
Coronary artery disease 715 (63.1%) 89 (58.9%) 243 (61.2%) 142 (59.4%) 241 (69.7%) 0.023
History of cerebrovascular accident 135 (11.9%) 12 (7.9%) 57 (14.4%) 29 (12.1%) 37 (10.7%) 0.170
Peripheral artery disease 170 (15.0%) 20 (13.2%) 56 (14.1%) 37 (15.5%) 57 (16.5%) 0.742
COPD 162 (14.3%) 18 (12.0%) 55 (13.9%) 38 (16.0%) 51 (14.8%) 0.717
Previous Cardiac Surgery 203 (17.9%) 13 (8.6%) 59 (14.9%) 29 (12.1%) 102 (29.5%) <0.001
Previous pacemaker implantation 111 (9.8%) 8 (5.3%) 27 (6.8%) 29 (12.1%) 47 (13.6%) 0.002
Mitral stenosis (moderate) 45 (4.4%) 4 (2.8%) 16 (4.4%) 11 (5.3%) 14 (4.7%) 0.725
STS-PROM = Society of Thoracic Surgery Predicted Risk Of Mortality; NYHA = New York Heart Association; eGFR = estimated glomerular filtration rate; COPD = chronic
obstructive pulmonary disease.
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Among 1133 eligible patients undergoing TAVI between 2007
and 2016, 38 (3.4%) patients were categorized as Stage 0, 113
(10.0%) as Stage 1, 397 (35.0%) as Stage 2, 239 (21.1%) as Stage 3,
and 346 (30.5%) as Stage 4. Overall, the mean age in the cohort
was 82.1 ± 6.3 years, mean STS PROM was 6.0 ± 4.2, and 50.6% of
the patients were female. Patients in more advanced stages tended
to have higher STS-PROM scores, more severe heart failure symp-
toms (NYHA III or IV), worse kidney function, and more frequently
had a history of coronary artery disease, previous cardiac surgery,
and permanent pacemaker implantation (Table 1).
There was a stepwise increase in all-cause and cardiovascular
mortality rates at 1 year according to increasing stages of sec-
ondary cardiac damage: 5.4% and 0% in Stage 0, 5.3% and 1.8% in
Stage 1, 8.9% and 5.9% in Stage 2, 17.7% and 12.9% in Stage 3, and
25.8% and 19.9% in Stage 4, respectively (Fig. 1). After multivariable
adjustment, increasing stages of cardiac damage gradually corre-
lated with all-cause mortality (Stage 2 vs. Stage 0–1: HR 1.54,
95% CI 0.71–3.33, p = 0.273; Stage 3 vs. Stage 0–1: HR 2.80, 95%
CI 1.30–6.03, p = 0.008; Stage 4 vs. Stage 0–1: HR 4.46, 95% CI
2.14–9.30, p < 0.001) and cardiovascular mortality (Stage 2 vs.
Stage 0–1: HR 3.93, 95% CI 0.92–16.73, p = 0.064; Stage 3 vs. Stage
0–1: HR 7.67, 95% CI 1.82–32.35, p = 0.006; Stage 4 vs. Stage 0–1:
HR 13.27, 95% CI 3.23–54.62, p < 0.001) at 1 year (Table 2). In a sen-
sitivity analysis excluding patients with comorbidities that mayTable 2




























cause cardiac damage independently of AS, the trends were consis-
tent; all-cause and cardiovascular mortality rates gradually
increased with advancing stages of secondary cardiac damage
(all-cause mortality: 0% in Stage 0–1, 6.3% in Stage 2, 22.8% in Stage
3, 27.7% in Stage 4; cardiovascular mortality: 0% in Stage 0–1, 4.5%
in Stage 2, 13.8% in Stage 3, 15.6% in Stage 4) (Table 3).
4. Discussion
By integrating current guideline recommendations of RV dys-
function into the proposed staging system of pre-procedural car-
diac damage [12,14], we identified a substantially higher
proportion of patients with advanced stages of disease as com-
pared to the two previous studies (31% in Stage 4 as compared to
4–9% in the studies by Généreux and Fukui, respectively). The pro-
portion was even higher than that of the study in symptomatic sev-
ere AS patients, in which RV dysfunction was assessed by
TAPSE < 1.6 cm [9]. The difference may be attributed to the older
age and higher risk nature of TAVI patients compared to the cohort,
or a stricter cut-off of TAPSE than that of the current guideline rec-
ommendations [11,12]. The refined staging system provided accu-
rate prognostic value in patients undergoing TAVI. Stage 4, Stage 3,
and Stage 2 conferred a 4.5-fold, 3-fold, and 1.5-fold increased risk
of all-cause mortality and a 13-fold, 8-fold, and 4-fold increased
risk of cardiovascular mortality, respectively, compared with Stage

























Sensitivity analysis excluding patients with other comorbidities potentially causing cardiac damage.
Stage 0 or 1 Stage 2 Stage 3 Stage 4 Crude risk ratios
Stage 2 vs. Stage 0–1 Stage 3 vs. Stage 0–1 Stage 4 vs. Stage 0–1
n = 48 n = 113 n = 62 n = 63 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
At 1 year














Continuity corrected risk ratios (95% confidence intervals) with p-values from Fisher’s exact tests are provided.
T. Okuno, D. Heg, J. Lanz et al. IJC Heart & Vasculature 33 (2021) 100768umented cardiac damage may have resulted from comorbidities
rather than AS [6,7]; in the present analysis, the prognostic value
of the cardiac damage staging system was maintained even after
exclusion of patients with relevant comorbidities potentially asso-
ciated with cardiac injury.
A significant number of patients with AS may undergo valve
replacement only once cardiac damage has already occurred. Inte-
grating a refined definition of RV dysfunction increased the sensi-
tivity of the staging system to identify patients at increased risk of
death after TAVI. The implications of our findings are fourfold. First,
quantitative assessment of cardiac damage in accordance with
guideline recommendations [12,14] improves reproducibility of
the proposed staging system. Second, a more sensitive identifica-
tion of patients prior to stage 4 cardiac damage may refine the tim-
ing of intervention for AS and improve outcomes. Third,
recognition of advanced stages of cardiac damage may improve
risk assessment of patients undergoing TAVI, and modulate subse-
quent follow-up and management strategies. Fourth, the staging
system may be integrated into the decision-making process
whether to perform TAVI or not in elderly patients with multiple
comorbidities who are at risk of treatment futility of TAVI.
5. Study limitations
Several limitations should be acknowledged when interpreting
the present analysis. First, about one third of patients were
excluded from the present analysis due to incomplete echocardio-
graphic assessment, which may have resulted in some degree of
selection bias. Second, all patients were recruited at a single
high-volume center. Finally, despite multivariate analyses, the pos-
sibility of residual confounding cannot be excluded.
6. Conclusions
A significant number of patients with AS underwent TAVI only
once cardiac damage has already occurred. Integrating an echocar-
diographic guideline-based definition of RV dysfunction increased
the sensitivity of the staging system to identify patients at
increased risk of death after TAVI.
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